How are you utilizing subcutaneous Nivolumab in genitourinary cancers?   

Would you use SQ Nivolumab for the initial treatment of RCC (Cabo/Nivo or Ipi/Nivo) or adjuvant treatment in MIBC? How do you counsel patients on balancing time toxicity with financial toxicity?